| Literature DB >> 28893675 |
Erin E Krebs1, Agnes C Jensen2, Sean Nugent2, Beth DeRonne2, Indulis Rutks2, David Leverty2, Amy Gravely2, Siamak Noorbaloochi3, Matthew J Bair4, Kurt Kroenke4.
Abstract
This manuscript describes the study protocol, recruitment outcomes, and baseline participant characteristics for the Strategies for Prescribing Analgesics Comparative Effectiveness (SPACE) trial. SPACE is a pragmatic randomized comparative effectiveness trial conducted in multiple VA primary care clinics within one VA health care system. The objective was to compare benefits and harms of opioid therapy versus non-opioid medication therapy over 12months among patients with moderate-to-severe chronic back pain or hip/knee osteoarthritis pain despite analgesic therapy; patients already receiving regular opioid therapy were excluded. Key design features include comparing two clinically-relevant medication interventions, pragmatic eligibility criteria, and flexible treat-to-target interventions. Screening, recruitment and study enrollment were conducted over 31months. A total of 4491 patients were contacted for eligibility screening; 53.1% were ineligible, 41.0% refused, and 5.9% enrolled. The most common reasons for ineligibility were not meeting pain location and severity criteria. The most common study-specific reasons for refusal were preference for no opioid use and preference for no pain medications. Of 265 enrolled patients, 25 withdrew before randomization. Of 240 randomized patients, 87.9% were male, 84.1% were white, and age range was 21-80years. Past-year mental health diagnoses were 28.3% depression, 17% anxiety, 9.4% PTSD, 7.9% alcohol use disorder, and 2.6% drug use disorder. In conclusion, although recruitment for this trial was challenging, characteristics of enrolled participants suggest we were successful in recruiting patients similar to those prescribed opioid therapy in usual care. Published by Elsevier Inc.Entities:
Keywords: Analgesics; Back pain; Chronic pain; Opioid analgesics; Osteoarthritis
Mesh:
Substances:
Year: 2017 PMID: 28893675 DOI: 10.1016/j.cct.2017.09.003
Source DB: PubMed Journal: Contemp Clin Trials ISSN: 1551-7144 Impact factor: 2.226